The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Emerging approaches being explored for AL amyloidosis
Ronald Witteles, MD, Stanford University, Stanford, CA, comments on the current therapeutic landscape for light chain (AL) amyloidosis, highlighting the significant progress made in lowering light chain levels and directly targeting clonal plasma cells, notably with the approval of daratumumab. Dr Witteles also emphasizes his enthusiasm for the potential of bispecific antibodies and CAR-T therapy for AL amyloidosis following positive early data. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
